Every 8-K that CTT PHARMACEUTICAL HLDGS (CTTH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CTTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTTH filings page.
CTT Pharmaceutical Holdings, Inc. says it is submitting a response letter from the auditor associated with its prior Form 8-K. The auditor agrees with what the company previously filed.
CTT Pharmaceutical Holdings, Inc. (CTTH) disclosed that its relationship with its auditor has ended. The company stated there were no disagreements over accounting practices and said the auditor is no longer handling SEC reporting companies. CTT said it will begin looking for a new auditor and contact another auditor it has worked with before.
CTT Pharmaceutical Holdings, Inc. (CTTH) added Karen Larson as an independent board member. The announcement identifies her as a Certified Financial Planner (CFP) and says she has experience running companies.
Her background includes creating an analytical reporting business that was sold to Morningstar and serving as a Senior Vice President, Investment Banker at Chase Manhattan Bank. She has been a founder of Broad Avenue Studios, Inc. since 2017.
CTT Pharmaceutical Holdings, Inc. reports that the U.S. Patent and Trademark Office has approved a continuation-in-part patent for its micelle-based delivery technology, effective August 11, 2026. The patent adds protection for formulations delivering nicotine, vitamins, and caffeine and supports multiple dosage forms, including dissolvable strips, gum, pouches, lozenges, and dissolving tablets. The company describes this as part of its strategy to strengthen its patent portfolio around oral drug delivery systems designed for rapid onset, patient convenience, and efficient absorption across pharmaceutical, therapeutic, and nutraceutical markets.